Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)
A Pilot Study in Feasibility and Safety: Point of Care Testing With Thromboelastography (TEG) for Blood Product Transfusion in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Amy L Monroe, BS
- Phone Number: 412-609-6161
- Email: monroeal@upmc.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC Presbyterian Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient's requiring ECMO placement
Exclusion Criteria:
- Other than children less than 18 years of age, no one will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Pilot Arm
All subjects enrolled in the trial will be in the pilot group.
These subjects will have traditional laboratory coagulation and blood transfusion tests (baseline arterial blood gas (ABG), complete blood count (CBC), fibrinogen, platelet count, aPTT, PT, anti-Xa, ACT), as well as thromboelastograph (TEG).
Pertinent TEG results will include: heparinase-kaolin TEG maximum amplitude (MA) in millimeters (mm), heparinase-kaolin TEG r-time in seconds, heparinase-kaolin TEG alpha angle in degrees, and TEG functional fibrinogen (FLEV) MA in mm.
|
A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants Whose Blood Management Care Follows a TEG Algorithm 90% of the Time
Time Frame: From time patient is placed on ECMO to 30-days post ECMO initiation
|
From time patient is placed on ECMO to 30-days post ECMO initiation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Transfusions Required While on ECMO
Time Frame: From the time patient is placed on ECMO to 30-days post ECMO initiation
|
Number of patients who required transfusions
|
From the time patient is placed on ECMO to 30-days post ECMO initiation
|
|
Number of Participants That Experience Bleeding or Thrombotic-related Adverse Events, Including Deep Venous Thrombosis or Pulmonary Embolus
Time Frame: From the time patient is placed on ECMO to 30-days post ECMO initiation
|
Number of patients who experienced bleeding while on ECMO
|
From the time patient is placed on ECMO to 30-days post ECMO initiation
|
|
Chest Tube Output and Overall Estimated Blood Loss
Time Frame: From time patient is placed on ECMO to 30-days post ECMO initiation
|
Average chest tube output
|
From time patient is placed on ECMO to 30-days post ECMO initiation
|
|
Time Between Transfusions
Time Frame: From time patient is placed on ECMO to 30-days post ECMO initiation
|
From time patient is placed on ECMO to 30-days post ECMO initiation
|
|
|
Type of Blood Products Transfused
Time Frame: From time patient is placed on ECMO to 30-days post ECMO initiation
|
From time patient is placed on ECMO to 30-days post ECMO initiation
|
|
|
Pump Exchanges Required
Time Frame: From time patient is placed on ECMO to 30-days post ECMO initiation
|
Number of participants who required pump exchanges
|
From time patient is placed on ECMO to 30-days post ECMO initiation
|
|
Oxygenator Exchanges
Time Frame: From time patient is placed on ECMO to 30-days post ECMO initiation
|
NUmber of participants who required oxygenator exchanges while on ECMO
|
From time patient is placed on ECMO to 30-days post ECMO initiation
|
|
Occurrence of Pump Circuit Clotting and Clots in the Oxygenator (Visible Clot Which Did Not Require Circuit/Pump Exchange)
Time Frame: From time patient is placed on ECMO to 30-days post ECMO initiation
|
Number of participants with pump circuit clotting
|
From time patient is placed on ECMO to 30-days post ECMO initiation
|
|
Time to Weaning From/Removal of ECMO
Time Frame: From time patient is placed on ECMO until time to weaning from ECMO
|
Average time to ECMO removal
|
From time patient is placed on ECMO until time to weaning from ECMO
|
|
Need for Surgical Intervention for Hemorrhage
Time Frame: From time patient is placed on ECMO to 30-days post ECMO initiation
|
Number of participants
|
From time patient is placed on ECMO to 30-days post ECMO initiation
|
|
Specimen Turn Around Time for Lab Tests (CBC, ACT, PT, PTT, Anti-Xa, INR, Platelet Count) and TEG Results
Time Frame: From time patient is placed on ECMO to 30-days post ECMO initiation
|
From time patient is placed on ECMO to 30-days post ECMO initiation
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Stephen Esper, MD, MBA, University of Pittsburgh Medical Center
Publications and helpful links
General Publications
- Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth. 2009 Sep;13(3):154-75. doi: 10.1177/1089253209347384.
- Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004;114(5-6):321-7. doi: 10.1016/j.thromres.2004.06.028.
- Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs. 1999 Nov;23(11):979-83. doi: 10.1046/j.1525-1594.1999.06451.x.
- Colby CE, Sheehan A, Benitz W, Van Meurs K, Halamek LP, Moss RL. Maintaining adequate anticoagulation on extracorporeal membrane oxygenation therapy: Hemochron Junior Low Range versus Hemochron 400. J Extra Corpor Technol. 2003 Mar;35(1):35-8.
- Reiner JS, Coyne KS, Lundergan CF, Ross AM. Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn. 1994 May;32(1):49-52. doi: 10.1002/ccd.1810320112.
- Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994 Dec;108(6):1076-82.
- Afshari A, Wikkelso A, Brok J, Moller AM, Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007871. doi: 10.1002/14651858.CD007871.pub2.
- Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999 Feb;88(2):312-9. doi: 10.1097/00000539-199902000-00016.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY19070239
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.